Brief: Phasebio Pharmaceuticals Posts Q3 Loss Per Share $0.40

PhaseBio Pharmaceuticals

14/11/2019 13:52

Nov 14 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND
RECENT
CORPORATE PROGRESS
    * Q3 LOSS PER SHARE $0.40
    * Q3 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES
DATA
    * QTRLY TOTAL REVENUE $241,000 VERSUS $411,000
    * SEES INITIATION OF PHASE 3 TRIAL OF PB2452 IN 1Q 2020
    * REPORTING OF PB1046 PHASE 2B TRIAL RESULTS IN 2H 2020
    * PHASEBIO PHARMACEUTICALS - CASH AND CASH EQUIVALENTS AT
SEPT 30,
WERE $81.8 MILLION, COMPARED TO $61.0 MILLION AT DECEMBER 31,
2018

Source text for Eikon:  ID:nGNX2Pck0H 
Further company coverage:  PHAS.O 

 ((Briefs@thomsonreuters.com;))